Gene Express, Inc. today announced that it has licensed to Gene Logic Inc. (NASDAQ: GLGC) its patented StaRT-PCR™ (Standardized Reverse Transcription Polymerase Chain Reaction™) and SEM Center™ (Standardized Expression Measurement Center™) technology for the standardized measurement of gene expression. Terms of the agreement were not disclosed.
StaRT-PCR is a unique method of measuring transcript abundance that incorporates proprietary reagents known as SMIS™ (Standardized Mixture of Internal Standards) that provide integrated quality control for each measurement. StaRT-PCR meets all of the analytical performance characteristics required by the U.S. Food and Drug Administration (FDA) to support pharmacogenomic data submissions in support of clinical trials. StaRT-PCR also meets the criteria defined by the Clinical Laboratory Improvement Amendment of 1988 (CLIA) to support the use of genomic biomarkers for diagnostic testing.
Gerald Vardzel, CEO of Gene Express, said, "This is our first commercial SEM Center licensing agreement and it represents an important milestone in our development. We are very pleased to have our technology utilized by such a well respected player and pioneer in the genomics field."
Dean Keser, Vice President Genomics Operations and Services, said, "Gene Express' StaRT-PCR technology platform provides Gene Logic with a key tool to perform high-quality, highly reproducible PCR to enhance our customers' ability to discover and prioritize gene targets and biomarkers for pharmacogenomic applications."
About Gene Express, Inc.
Gene Express, Inc. accelerates and enables drug development by providing standardized and quantitative gene expression data. The Company's proprietary and patented StaRT-PCR™ (Standardized Reverse Transcription Polymerase Chain Reaction) platform technology for measuring transcript abundance levels in human samples, including whole blood is being used by numerous biotechnology and pharmaceutical concerns, as well as leading academic centers. The Company's $3 billion focus market for licensing and contract services includes the drug development, academic research and molecular diagnostics segments. Additional information is available on the Company's website at www.geneexpressinc.com.
Any forecasts, plans, projections and other information contained in this press release describing events or results that may occur in the future are "forward-looking statements" as defined in the United States Private Securities litigation Reform Act of 1995. Forward-looking statements are subject to risks, uncertainties and important factors that are beyond the control of the Company that could cause actual results and events to differ materially from the results presently anticipated or projected. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to this cautionary statement. All forward-looking statements contained herein speak only as of the date of this release and are based on current expectations. The Company disclaims any obligation to update or revise any forward-looking statements.
Contact: Rachel Levine The Global Consulting Group Tel: 646-284-9439 E: Email Contact
SOURCE: Gene Express, Inc.